1. Home
  2. BCG vs SNTI Comparison

BCG vs SNTI Comparison

Compare BCG & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCG

Binah Capital Group Inc.

HOLD

Current Price

$1.48

Market Cap

26.7M

Sector

N/A

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.94

Market Cap

29.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCG
SNTI
Founded
2016
2016
Country
United States
United States
Employees
150
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.7M
29.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BCG
SNTI
Price
$1.48
$0.94
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
27.4K
167.7K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$56.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.36
$0.77
52 Week High
$3.44
$2.88

Technical Indicators

Market Signals
Indicator
BCG
SNTI
Relative Strength Index (RSI) 37.06 49.05
Support Level $1.52 $0.87
Resistance Level $2.49 $1.03
Average True Range (ATR) 0.09 0.06
MACD 0.01 -0.00
Stochastic Oscillator 20.01 41.25

Price Performance

Historical Comparison
BCG
SNTI

About BCG Binah Capital Group Inc.

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: